Use of Recombinant Factor VIIa (NovoSeven®) to Reduce Postoperative Bleeding after Total Hip Arthroplasty in a Patient with Cirrhosis and Thrombocytopenia

Slappendel, R.; Huvers, F. C.; Benraad, B.; Nováková, I.R.O.; Hellemondt, Gijs G. van

doi:10.1097/00000542-200206000-00040

Cited by 34 publications

(19 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous published studies in literature reported that the use of activated recombinant factor VII, showed hemostatic efficacy in patients with impaired haemostasis such as hemophilia A or B [12]. This was owing to the formation of a complex with tissue factor (TF), which is a membrane bound glycoprotein, available in the wound bed.…”

Section: Discussionmentioning

confidence: 99%

Effect of activated recombinant factor VII versus tranexamic acid infusion on bleeding during spine surgery, randomized, controlled, double blinded trial

ELShamaa

Elokda

2015

Egyptian Journal of Anaesthesia

View full text Add to dashboard Cite

Background: Antifibrinolytic drugs, such as tranexamic acid are medications that facilitate hemostasis and decrease blood loss and the need for blood transfusion during major surgery. Activated recombinant coagulation factor VII is a novel hemostatic agent, studies revealed that it is helpful hemostatic in disorders with impaired hemostasis, as well as in patients with normal hemostatic function to minimize perioperative blood loss. This study aimed to compare the efficacy of activated recombinant factor VII with tranexamic acid in reducing the perioperative blood loss. Methods: 50 patients undergoing spine surgery were enrolled in this study. Group A patients were given activated recombinant factor VII and group T patients given tranexamic acid. In both groups, anesthesia was induced using fentanyl 3 lg/kg and propofol 2 mg/kg; muscle relaxation was initiated using cisatracurium 0.2 mg/kg. Transfusion of blood and its products was done according to a value guide. The primary outcome variable of the study was the total volume of blood loss in the perioperative period. Secondary outcome variables include perioperative transfusion requirement, and the number of patients who needed transfusion, as well as time of operation. A P-value less than 0.05 is considered statistically significant. Results: The current study showed that the total perioperative blood loss in group A was significantly lower than group T. None of the patients required ICU admission, as well as reentry to operating theater. Furthermore, no significant difference was detected in the number of patients needed blood transfusion. Intraoperative bleeding was associated with a slight decrease of hemoglobin in group A. Conclusion: The present study concluded that administration of activated recombinant factor VII in spine surgery reduces the total perioperative blood loss and the total volume of intraoperative blood transfusion compared with tranexamic acid, with no evidence of adverse effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of activated recombinant factor VII versus tranexamic acid infusion on bleeding during spine surgery, randomized, controlled, double blinded trial

ELShamaa

Elokda

2015

Egyptian Journal of Anaesthesia

View full text Add to dashboard Cite

show abstract

“…5Y13 Slappendel et al 15 reported the case of an adult patient with liver cirrhosis and hypersplenism requiring total hip arthroplasty treated with rFVIIa. Dutton et al 16 showed that the administration of rFVIIa contributed to successful control of hemorrhage in critically ill patients with trauma.…”

Section: Discussionmentioning

confidence: 99%

Successful Use of Recombinant Factor VIIa (NovoSeven) in Children With Compartment Syndrome

Alioğlu¹,

Avcı²,

Baskın³

et al. 2006

Journal of Pediatric Orthopaedics

View full text Add to dashboard Cite

Compartment syndrome (CS) is an uncommon bleeding manifestation in patients with liver failure and end-stage renal disease (ESRD). Although prompt intervention is paramount in preventing the tissue necrosis and the permanent functional deficits that may be associated with untreated CS, the indications for initiating therapies for children with CS are not standardized. In this report, we present 2 children, one with ESRD and the other with liver failure, who have CS related to life-threatening bleeding complications and were treated with recombinant factor VIIa (rFVIIa). In conclusion, treatment decisions for patients with CS should be made on a case-by-case basis. The use of rFVIIa is an effective and safe treatment in children with liver failure and ESRD. Surgical treatment should be preferred in patients with CS. However, in patients who have a coagulation defect, the first priority is to correct the clotting deficiency. The use of rFVIIa is a treatment option in children with CS due to a coagulation defect.

show abstract

“…28 Several case reports demonstrated the use of rFVIIa to either control bleeding in patients with liver disease or for the prophylaxis of bleeding in patients with liver disease and prolonged prothrombin times undergoing invasive procedures. [29][30][31][32][33] A few studies evaluated the procoagulant effects of rFVIIa in patients with liver disease utilizing methods such as thrombin generation assays and thromboelastography. 34,35 Although much of this data is preliminary and not based on controlled clinical trials, it is likely that rFVIIa is effective in the management of coagulopathy of liver failure.…”

Section: Liver Diseasementioning

confidence: 99%

Novel Hemostatic Agents: A Focus on Recombinant Factor VIIa and Factor XIII

Young

2004

Transfus Alt Transfus Med

View full text Add to dashboard Cite

Use of Recombinant Factor VIIa (NovoSeven®) to Reduce Postoperative Bleeding after Total Hip Arthroplasty in a Patient with Cirrhosis and Thrombocytopenia

Cited by 34 publications

References 9 publications

Effect of activated recombinant factor VII versus tranexamic acid infusion on bleeding during spine surgery, randomized, controlled, double blinded trial

Effect of activated recombinant factor VII versus tranexamic acid infusion on bleeding during spine surgery, randomized, controlled, double blinded trial

Successful Use of Recombinant Factor VIIa (NovoSeven) in Children With Compartment Syndrome

Novel Hemostatic Agents: A Focus on Recombinant Factor VIIa and Factor XIII

Contact Info

Product

Resources

About